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Purpose: The incidence of accidentally detected small renal
tumors is increasing throughout the world. In this multi-
institutional study performed in Korea, histopathological
characteristics of contemporarily surgically removed renal
tumors were reviewed with emphasis on tumor size. Materials
and Methods: Between January 1995 and May 2005, 1,702
patients with a mean age of 55 years underwent surgical
treatment at 14 training hospitals in Korea for radiologically
suspected malignant renal tumors. Clinicopathological factors
and patient survival were analyzed. Results: Of the 1,702
tumors, 91.7% were malignant and 8.3% were benign. The
percentage of benign tumors was significantly greater among
those 4 cm (13.2%) than those > 4 cm (4.5%) (p < 0.001).
Among renal cell carcinoma patients, the percentage of tumors
classed as stage T3 was significantly less among tumors
4 cm (5.2%) than those > 4 cm (26.8%) (p < 0.001). The
percentage of tumors classed as Fuhrman's nuclear grades
3 was also significantly less among tumors 4 cm (27.3%)
than tumors > 4 cm (50.9%) (p < 0.001). The 5-year cancer-
specific survival rate was 82.7%, and T stage (p < 0.001), N
stage (p < 0.001), M stage (p = 0.025), and Fuhrman's nuclear
(p < 0.001) grade were the only independent predictors of
cancer-specific survival. Conclusion: In renal tumors, small
tumor size is prognostic for favorable postsurgical histopatho-
logies such as benign tumors, low T stages, and low Fuhrman's
nuclear grades. Our observations are expected to facilitate
urologists to adopt function-preserving approach in the
planning of surgery for small renal tumors with favorable
predicted outcomes.
Key Words: Kidney neoplasms, renal cell carcinoma, nephr-
ectomy, surgical pathology
INTRODUCTION
Renal cell carcinoma (RCC) accounts for about
3% of all adult cancers. Because of the relative
rarity of benign renal tumors, it is a common
practice for urologists to consider any renal mass
that enhances with intravenous contrast on
computed tomography (CT) scan as a malignancy.
If it is localized, they tend to treat such masses
radically unless there is definite evidence of a
benign pathology. The proportion of incidentally
discovered renal tumors is increasing because of
the widespread use of abdominal ultrasound and
CT scans for reasons unrelated to renal tumors.1,2
Characteristically, these tumors are small and
present with low stages and grades.2-4 Thus, a
variety of less invasive and function-preserving
treatment modalities are being applied to small
tumors of 4 cm or less in diameter with oncologi-
cal outcomes similar to those of radical nephrec-
tomy.5,6 Furthermore, data from several institu-
tions indicate that the percentage of benign
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pathologies for renal tumors less than 4 or 5 cm
in diameter is high (20 - 33%), which adds further
support for implementation of function-pre-
serving nephron-sparing surgery in this cohort.4,7,8
However, the true incidence of benign renal
tumors is difficult to estimate because clinical
diagnoses made using modern radiography
techniques are often incorrect. On the other hand,
the proportion of pathologically proven benign
tumors reported by centers may be biased. This
multi-institutional study was initiated to estimate
the true incidence of benign renal neoplasms
among surgically treated renal tumors, particularly
tumors of 4 cm or less in diameter. Pathological
features and oncological outcome of RCC were
also analyzed according to tumor size.
MATERIALS AND METHODS
Fourteen training hospitals (13 university
hospitals and 1 hospital affiliated with the Korean
National Institute of Health) participated in this
retrospective study. These hospitals represent
about 17% of all official urology training centers
in Korea.
All patients aged 16 years or older who under-
went radical nephrectomies or nephron-sparing
surgery because of clinical diagnoses of renal
malignancy from January 1995 to May 2005 were
included in this study. Clinical data were
collected by chart review and recorded. Surgical
pathology reports were reviewed and data
including histopathological diagnosis and size,
pathological stage, and grade of tumor were
recorded. RCC was pathologically staged
according to the 1997 TNM system and graded
according to Fuhrman's nuclear grading system.9
The size of the tumor was defined as the longest
diameter described in the pathology report but in
the absence of such information, it was defined as
the longest diameter measured using ultrasound,
CT, or magnetic resonance imaging. In case of
multifocal tumors, the size of the greatest tumor
was recorded.
Patients with a final pathological diagnosis of
transitional cell carcinoma were excluded from
this study. Patients with an angiomyolipoma
(AML) larger than 4 cm in diameter were also
excluded because most underwent surgery to
prevent or treat complications of a radiologically
confirmed AML rather than a suspected
malignancy. For patients who underwent either
radical nephrectomy or nephron-sparing surgery
more than once, only the first operation was
recorded.
Histopathological diagnosis, T stage, and grade
were stratified according to tumor size. These
variables were also classed into those associated
with tumors equal to or less than 4 cm in diameter
and those associated with tumors larger than 4 cm
in diameter. Student t test and chi-square test
were used to compare variables between groups.
Kaplan-Meier method and log-rank test were used
for all univariate survival analyses, and Cox
regression model was used for multivariate
analysis.
RESULTS
A total of 1,702 patients with known
pathological diagnoses were included in this
study. Pathological measurements of tumor size
were available for 1,654 patients and radiological
measurements of tumor size were available for the
remaining 48. The mean patient age was 55.0
years (range, 16 - 86 years) and the male to female
ratio was 2.04 : 1 (Table 1). Among the 1,618
patients in which the mode of presentation was
known, 1,181 (73.0%) were incidental. Radical
nephrectomy was performed on 1,591 patients
(93.5%) and partial nephrectomy was performed
on 111 (6.5%). Among radical nephrectomies, 39
kidneys (2.5%) had more than 1 focus of tumor.
The mean tumor size was 5.4 cm (range, 0.7 - 24.0
cm).
The pathological diagnosis was malignancy in
1,561 patients (91.7%) and benign tumor in 141
(8.3%). The mean tumor size was 5.5 ± 3.1 cm and
4.1 ± 3.1 cm for malignancy and benign tumors,
respectively, and the difference was statistically
significant (p < 0.001). When tumors were strati-
fied according to size, the percentage of benign
tumors increased as size decreased from 5.9% for
tumors larger than 7 cm in diameter to 64.3% for
tumors 1 cm or less in diameter (Table 2).
RCC was diagnosed in 1,546 patients. Two
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hospitals failed to present information on RCC
subtypes, N stage, M stage, and oncological
outcome data. Among 1,316 RCC patients from
12 hospitals, clear cell subtype accounted for
83.9%, followed by papillary (6.0%), chromophobe
(5.0%), and others (Table 1). Pathological T stage
was available for 1,543 : 68.0% of patients were
classed as T1, 14.1% as T2, 16.5% as T3, and
1.4% as T4. When these tumors were stratified
according to size, the percentage of tumors
classed as T3 stage or higher decreased as size
decreased from 40.6% for tumors larger than 7
cm in diameter to 6.2% for tumors 2 cm or less
in diameter (Table 3).
Among 1,457 RCC patients for whom Fuhrman's
nuclear grade was available, 11.2% were classed
as grade 1, 47.8% as grade 2, 32.9% as grade 3,
and 8.2% as grade 4 (Table 4). When these tumors
were stratified according to size, the percentages
of grades 1 and 2 increased as size decreased
whereas the percentages of grades 3 and 4
decreased as size decreased.
Of the tumors, 743 (43.7%) were 4 cm or less in
diameter and 959 (56.3%) were larger than 4 cm
in diameter (Table 5). The percentage of benign
tumors was significantly greater for tumors equal
to or less than 4 cm in diameter (13.2%) than for
tumors larger than 4 cm in diameter (4.5%) (p <
0.001). Furthermore, in a subset of 99 tumors 4
cm or less in diameter that were treated by
partial nephrectomy, 36 (36%) were benign.
Among RCC patients, the percentage of tumors
classed as equal to or higher than stage T3 was
significantly lower for tumors equal to or less
than 4 cm in diameter (5.2%) than for tumors
larger than 4 cm in diameter (26.8%, p < 0.001).
The percentage of Fuhrman's nuclear grades 3
and 4 was significantly less for tumors equal to
or less than 4 cm in diameter (27.3%) than for
tumors larger than 4 cm in diameter (50.9%) (p <
0.001).
Pathological diagnoses for benign tumors equal
to or less than 4 cm in diameter were (in de-
creasing order of frequency) AML (41), benign
cyst (20), oncocytoma (19), cystic nephroma (2),
hemangioma (2), metanephric adenoma (2), and
others (9) (Table 6).
Oncological outcome data were available for
1,290 patients. Five-year overall and cancer-
Table 1. Clinicopathologic Characteristics of Patients
with Clinical Impression of Renal Malignancy Treated
Surgically
Characteristic Patients (n) %
Total 1,702
Mean age (yrs) (range) 55.0 (16 - 86)
Gender (male : female ratio) 2.04 : 1
Male 1,142 67.1
Female 560 32.9
Mode of presentation 1,618
Incidental 1,181 73.0
Symptomatic 437 27.0
Treatment 1,702
Radical nephrectomy 1,591 93.5
Partial nephrectomy 111 6.5
Tumor size (cm) (range) 5.4 (0.7 - 24.0)
Benign pathology 141 8.3
T stage (RCC) 1,543
1 1,049 68.0
2 217 14.1
3 254 16.5
4 21 1.4
N stage (RCC) 1,316
0 1,245 94.6
1 71 5.4
M stage (RCC) 1,316
0 1,218 92.6
1 98 7.4
Fuhrman's nuclear grade 1,457
G1 163 11.2
G2 696 47.8
G3 479 32.9
G4 119 8.2
Histological subtype 1,316
Clear cell 1,104 83.9
Papillary 79 6.0
Chromophobe 66 5.0
Collecting duct 5 0.4
Granular 20 1.5
Mixed 12 0.9
Sarcomatoid 9 0.7
Unclassified 2 0.2
Unknown 18 1.4
RCC, renal cell carcinoma.
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specific survival was 81.0% and 82.7%, respec-
tively (Fig. 1). The presence of symptom at
initial presentation, pathological T stage, N
stage, M stage, Fuhrman's nuclear grades and
tumor size were significant predictors of cancer-
specific survival (p < 0.001) whereas tumor
subtype was not (p = 0.779). On multivariate
analysis, T stage (p < 0.001), N stage (p < 0.001)
M stage (p = 0.025) and Fuhrman's nuclear (p <
0.001) grades were significant predictors of
cancer-specific survival.
DISCUSSION
In our patients, who constituted 13 - 15% of all
surgically managed renal tumor patients in Korea
during the past 11 years, the recent global trend
toward early diagnosis of small tumors in the
absence of symptoms was evident (73.0% of
tumors were incidental and 43.7% were equal to
or less than 4 cm in diameter). Moreover, the
clinical benefit of this trend was clearly evidenced
by an increase in the percentage of benign tumors
Table 3. Pathological T Stage T3 in Renal Cell Carcinoma Stratified according to Tumor Size*
Tumor size (cm)
No. of patients
Cumulative % T3
Total T3 (%)
1 5 0 (0) 0
1 - 2 124 8 (6.5) 6.2
2 - 3 266 10 (3.8) 4.6
3 - 4 245 15 (6.1) 5.2
4 - 5 197 27 (13.7) 7.2
5 - 6 216 37 (17.1) 9.2
6 - 7 128 31 (24.2) 10.8
> 7 362 147 (40.6) 17.8
All 1,543 275 (17.8)
*Among 1,546 renal cell carcinomas, pathological T stage data were available for 1,543.
Table 2. Histopathology of Renal Tumors Stratified according to Tumor Size
Tumor size (cm)
No. of patients (%)
Cumulative % benign
Malignancy Benign Total
1 5 (35.7) 9 (64.3) 14 64.3
1 - 2 124 (78.0) 35 (22.0) 159 25.4
2 - 3 268 (89.3) 32 (10.7) 300 16.1
3 - 4 248 (91.9) 22 (8.1) 270 13.2
4 - 5 199 (97.5) 5 (2.5) 204 10.9
5 - 6 217 (96.0) 9 (4.0) 226 9.5
6 - 7 130 (95.6) 6 (4.4) 136 9.0
> 7 370 (94.1) 23 (5.9) 393
All 1,561 (91.7) 141 (8.3) 1,702
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and a decrease in the percentage of tumors with
high T stages and grades as tumor size decreased.
In a review of 131 consecutive patients who
underwent radical nephrectomy between 1989
and 1993, Jayson and Sanders1 found that 61% of
tumors were discovered incidentally, which
contrasts sharply with the results of Skinner et
al.,10 who reported that 7% of tumors were in-
cidental between 1935 and 1965 (when CT scanning
was not available). A progressive increase of
incidental tumors was also observed in Europe:
from 13.0% in 1982 - 1983 to 59.2% in 1996 - 1997.3
Patard et al.2 reviewed 729 cases of surgically
treated renal tumors conducted over 20 years that
were divided into 3 distinct periods and observed
significant change in the percentage of incidental
tumors (24.4% to 51.1%), tumors of 4 cm or
smaller in diameter (12.2% to 26.9%), and benign
tumors (4.6% to 9.8%) from period 1 to 3. In a
retrospective analysis of patients in whom renal
tumors were managed surgically, Lee et al.5 noted
a significant 32% decrease in tumor size from the
first to the last year of a recent decade. In that
study, 252 of 670 (38%) patients had tumors equal
to or less than 4 cm in diameter of which 79%
were discovered incidentally. Similarly, in a recent
prospective analysis of 106 renal tumors, 47%
were 4 cm in diameter or smaller.8
Our finding that the incidence of benign tumors
among those 4 cm or less in diameter (13.2%) was
significantly greater than the incidence of benign
tumors among those larger than 4 cm in diameter
corroborates with similar reports by others,2,4,8
while the incidence is less than that reported
recently by some institutions. Unlike previous
studies, our study is a multi-institutional study of
14 training hospitals and, to our knowledge, is the
largest of its kind. Multi-institutional studies may
reflect the true epidemiology of diseases more
accurately than single-institution studies. The
Table 4. Fuhrman's Nuclear Grade in Renal Cell Carcinoma Stratified according to Tumor Size*
Tumor size (cm)
No. of patients (%)
G1 (%) G2 (%) G3 (%) G4 (%) Total
1 2 (40.0) 2 (40.0) 1 (20.0) 0 (0) 5
1 - 2 27 (22.7) 67 (56.3) 22 (18.5) 3 (2.5) 119
2 - 3 38 (15.0) 145 (57.1) 67 (26.4) 4 (1.6) 254
3 - 4 32 (13.9) 130 (56.3) 60 (26.0) 9 (3.9) 231
4 - 5 21 (11.1) 94 (49.7) 66 (34.9) 8 (4.2) 189
5 - 6 20 (9.8) 96 (46.8) 72 (35.1) 17 (8.3) 205
6 - 7 10 (8.2) 51 (41.8) 42 (34.4) 19 (15.6) 122
> 7 13 (3.9) 111 (33.4) 149 (44.9) 59 (17.8) 332
All 163 (11.2) 696 (47.8) 479 (32.9) 119 (8.2) 1,457
*Among 1,546 renal cell carcinomas, data on Fuhrman's nuclear grade were available for 1,457.
Fig. 1. Cancer-specific survival curve of 1,290 patients who
underwent radical or nephron-sparing surgery for renal
cell carcinoma.
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percentage of benign tumors reported by indivi-
dual institutions may be subject to inter-institu-
tional bias due to differences in policies regarding
the management of renal tumors. For instance,
some surgeons may prefer surgery for small
incidentally detected complex renal cysts or solid
renal tumors with equivocal fat density while
others will opt for regular follow-up assessment.
Consequently, a more aggressive attitude toward
equivocal tumors may result in a higher per-
centage of benign tumors. On the other hand,
multi-institutional studies reflect average results
from several institutions. Valeri et al.11 presented
data on 2139 renal solid tumors from surgeries at
5 French tertiary centers during 1 year. The
percentage of benign tumors in the subset of 722
tumors equal to or less than 4 cm in diameter
varied widely between centers and ranged from
4.7 to 29% with a mean of 8.7%, which was lower
than our result.
An association between nephron-sparing surgery
and a particularly high percentage of benign
tumors has been observed in our as well as other
studies. According to Marszalek et al.
7
who
reviewed a recent series of 129 patients who
underwent nephron-sparing surgery for renal
tumors less than 5 cm in diameter, 32.6% were
benign. Similarly, the incidence of benign
pathology in our subset of tumors equal to or less
than 4 cm in diameter and treated by partial
nephrectomy was 36%. The reason for this
association is not clear and could be criticized for
the lack of supporting evidence. However, it is
likely that small renal tumors exhibiting radiolo-
gical features favoring benignity that would have
been closely observed in the past are increasingly
being treated by nephron-sparing approach.
Accumulation of results from contemporary
nephron-sparing surgery series could elucidate
this issue in the future.
Table 5. Histopathological Characteristics of Renal Tumors according to Tumors 4 cm and > 4 cm*
No. of tumors 4 cm (%) No. of tumors > 4 cm (%) p value
Total pts 743 959
Pathology
Malignant 645 (86.8) 916 (95.5) < 0.001
Benign 98 (13.2) 43 (4.5)
T stage
1, 2 607 (94.8) 661 (73.2) < 0.001
3, 4 33 (5.2) 242 (26.8)
Fuhrman's grade
1, 2 443 (72.7) 416 (49.1) < 0.001
3, 4 166 (27.3) 432 (50.9)
*Data on pathological T stage and Fuhrman's nuclear grade were available for all 1,543 and 1,457 renal cell carcinomas,
respectively.
Table 6. Histopathology of Renal Tumors 4 cm in
Diameter
Patients (n) %
RCC 640 86.1
Other malignancy 5 0.7
AML 41 5.5
Benign cyst 20 2.7
Oncocytoma 19 2.6
Cystic nephroma 2 0.3
Hemangioma 2 0.3
Metanephric adenoma 2 0.3
Others 12 1.6
RCC, renal cell carcinoma; AML, angiomyolipoma.
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The ethnic difference between Asians and
Caucasians may be a potential cause for the
relatively low incidence of benign tumors in our
study. To our knowledge, however, no study has
properly addressed this issue. The percentage of
oncocytoma was 2.6% in our subset of renal
tumors equal to or less than 4 cm in diameter
and 2.0% for all tumors (data not shown).
Oncocytoma is the most common benign renal
cortical tumor and represents 3-7% of renal
tumors although the incidence seems to have
increased recently.7,8,12 Although the reason for
the distinctively low percentage of oncocytoma in
our series is unclear, this may indicate that there
are ethnic differences in the incidence of
oncocytoma. To our knowledge, the greatest
number of renal oncocytomas treated at a single
center in Asia (16) was reported in the English
literature by Yen et al.,13 who emphasized the
relative rarity of oncocytoma in Eastern compared
to Western countries and suggested genetic or
environmental differences or simple underdiagnosis
as possible causes. However, the proportional
contribution of oncocytoma to all treated renal
tumors was not given in their study. Our study
presents objective evidence to support the view
that Eastern people are, for unknown reasons,
less prone to oncocytoma than Western people. A
low incidence of oncocytoma may have
contributed to the comparatively low percentage
of benign tumors in our study.
In contrast to the low incidence of oncocytoma,
a relatively high incidence of AML in our patients
could be pointed out. As with oncocytoma, ethnic
difference could be suggested as a possible
reason but no pertaining evidence is found in the
literature. On the other hand, our 5.5% incidence
of AML may not be unusually high as the
reported incidence of AML among surgically
treated renal tumors ranges from 2 to 5.9%.
4,7,14,15
In 14% of AMLs, fat cannot be identified with CT
scan, presumably related to a reduced proportion
of mature adipose tissue.16 In these fat poor
AMLs, a definite diagnosis cannot be made by
the imaging technique and should be managed
like all enhancing renal masses.17 It is unlikely
that fat content was not well examined by
preoperative CT scan in our small AML cases. It
is probable that most of these tumors fall under
the category of fat poor AML although patholo-
gical review was not performed to confirm that
these tumors satisfy the pathological definition of
fat poor AML as suggested by Milner et al.17
The increased incidence of benign small renal
tumors revealed by our series and those of
others may increase awareness of the usefulness
of preoperative biopsy. It can be assumed that
the preoperative biopsy rate was negligible in
our series because none of the participating
centers were performing it routinely at the time
of the study. In a prospective study on 100
consecutive preoperative renal tumor biopsies,
accuracy was 72%, sensitivity was 83%, and
specificity was 33%.18 In another retrospective
study of percutaneous renal mass biopsy, the
sensitivity and negative predictive value for
masses 3 cm and less in diameter were 84% and
60%, respectively.19 Because the accuracy of renal
mass biopsy is low, we believe that the value of
preoperative biopsy for obviating unnecessary
surgical excision of small renal masses is
questionable.
Our study is limited by the failure to have the
pathological slides reviewed and agreed upon by
the pathologists of the participating centers.
Although the reviewing process would have
strengthened the validity of the pathological data,
it was not considered vital for our study. In a
previous multicenter study of RCC conducted by
pathologists at 20 institutes in Korea, the pro-
portions of each histological subtype 86.3% clear
cell, 7.3% papillary, and 6.16% chromophobe
were similar to ours, supporting the validity of
our subtype data.20
In this multi-institutional study on the histopa-
thology of surgically removed renal tumors,
small tumor size was an important predictor of
favorable histopathologies such as benign tumors,
low T stages, and low Fuhrman's nuclear grades.
These data and the high incidence of benign
pathology in our small subset of partial nephrec-
tomy performed for tumors equal to or less than
4 cm should facilitate the adoption of partial
nephrectomy by Korean urologists. However,
accumulation of experience and oncological
outcome data will be necessary to firmly support
partial nephrectomy as a viable surgical option
for small renal tumors.
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